GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?

Documents similaires

• Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
  par: Lien‐Chung Wei, et autres
  Publié: (2025)
• Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
  par: Calvin C. Wu, et autres
  Publié: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  par: Tommaso Bucci, et autres
  Publié: (2025)
• Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
  par: W. Timothy Garvey, et autres
  Publié: (2024)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  par: Hans Johnson, et autres
  Publié: (2025)